Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Coeptis Therapeutics Holdings (COEPW) over the last 5 years, with Q3 2025 value amounting to $4.7 million.

  • Coeptis Therapeutics Holdings' Shares Outstanding (Weighted Average) fell 8807.96% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 8807.96%. This contributed to the annual value of $1.9 million for FY2024, which is 4983.58% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported Shares Outstanding (Weighted Average) of $4.7 million as of Q3 2025, which was down 8807.96% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Shares Outstanding (Weighted Average) registered a high of $39.8 million during Q3 2024, and its lowest value of $1.3 million during Q4 2023.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $14.8 million, with a median of $12.6 million in 2022.
  • In the last 5 years, Coeptis Therapeutics Holdings' Shares Outstanding (Weighted Average) soared by 17718.94% in 2022 and then plummeted by 9135.43% in 2025.
  • Over the past 5 years, Coeptis Therapeutics Holdings' Shares Outstanding (Weighted Average) (Quarter) stood at $10.9 million in 2021, then surged by 30.98% to $14.3 million in 2022, then plummeted by 91.01% to $1.3 million in 2023, then surged by 49.84% to $1.9 million in 2024, then surged by 146.54% to $4.7 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $4.7 million in Q3 2025, compared to $3.7 million in Q2 2025 and $3.1 million in Q1 2025.